CLINICAL TRIALS PROFILE FOR NASALCROM
✉ Email this page to a colleague
All Clinical Trials for NASALCROM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01175525 ↗ | Treatment of Acute Stroke With Cromolyn(Single Dose) | Unknown status | Wolfson Medical Center | Phase 3 | 1969-12-31 | Mastocytes were proven to have a central rule in their development of the lipoid plaque of the vascular system. Mastocytes also has an important role in the stabilisation of the plaque in the building of the brain barrier. Different animal studies show that the inhibition of the mastocyte activity decreases significantly the risk of secondary bleeding post ischaemic stroke.It was also shown that post stroke inflammation process was also blocked by the inhibition of mastocytes.Other studies showed up to 100% decrease in the brain barrier disruption and post stroke oedema, after treatment with mastocyte inhibitors. Cromolyn is a synthetic drug which has an anti-allergic effect by inhibition of the mastocytes. This drug is a well known,safe drug and is the main sub-substance that was used in the previously mentioned studies. |
NCT03794076 ↗ | Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia | Recruiting | Stanley Medical Research Institute | Phase 1/Phase 2 | 2019-04-01 | This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate. |
NCT03794076 ↗ | Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia | Recruiting | Vishwajit Nimgaonkar, MD PhD | Phase 1/Phase 2 | 2019-04-01 | This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NASALCROM
Condition Name
Clinical Trial Locations for NASALCROM
Trials by Country
Clinical Trial Progress for NASALCROM
Clinical Trial Phase
Clinical Trial Sponsors for NASALCROM
Sponsor Name